OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
November 18, 2010
New CER tools grant payers the evidence they need to control drug costs
November 01, 2010
Once silent, an emerging market raises its voice
Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges
With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East
There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?
The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation
The CEO should be able to communicate the vision of a merger-strategically, financially, operationally, and with the entire organization in mind
PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies
Pharm Exec sits down with an expert on regional marketing to ascertain what it takes to drive strong brand results
A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA